Digest Network Come funziona
Network
/
Società
Vi
Non verificato

ViiV Healthcare

Di cosa scriviamo

FarmaceuticaHIV, AIDS e malattie autoimmuniIndustriaSaluteScienza

16 comunicati stampa

Guarda tutti i comunicati
17/10/2025
Biotecnologia
Farmaceutica
HIV, AIDS e malattie autoimmuni
Sanità
Salute
Igiene alimentare
Medicina - Varie
Industria
ViiV Healthcare announces 96-week data reaffirming Dovato is as effective as Biktarvy in maintaining virological suppression of HIV-1 with significantly less weight gain
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
15/10/2025
Sanità
Management
Farmaceutica
Pubblico Esercizio/Vendita al dettaglio
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Biotecnologia
Scienza
Assistenza all'Infanzia
Vetrine/Shopping
Salute
Industria
Analisi di mercato
ViiV Healthcare’s CLARITY study shows long-acting cabotegravir more acceptable than lenacapavir injections after a single dose, with 90% preferring cabotegravir
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
09/10/2025
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Eventi
Fiere
ViiV Healthcare showcases breadth of clinical and real-world evidence at EACS and IDWeek 2025
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
14/07/2025
HIV, AIDS e malattie autoimmuni
Farmaceutica
Salute
Analisi di mercato
Industria
ViiV Healthcare data show 89% of treatment-naïve people with HIV choose to switch to long-acting injectable Vocabria + Rekambys from daily pills after achieving rapid viral suppression
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
14/07/2025
HIV, AIDS e malattie autoimmuni
Farmaceutica
Salute
Analisi di mercato
Industria
ViiV Healthcare data show 89% of treatment-naïve people with HIV choose to switch to long-acting injectable Vocabria + Rekambys from daily pills after achieving rapid viral suppression
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
14/07/2025
HIV, AIDS e malattie autoimmuni
Salute
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Industria
ViiV Healthcare extends voluntary licensing agreement with Medicines Patent Pool to enable access to innovative long-acting injectable HIV treatment
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
08/07/2025
Scienza
HIV, AIDS e malattie autoimmuni
Sanità
Biotecnologia
Farmaceutica
Salute
Eventi
Industria
ViiV Healthcare presents new data demonstrating positive real-world impact of its innovative long-acting injectables for HIV at IAS 2025
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
12/03/2025
Eventi
Fiere
Industria
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
12/03/2025
Eventi
Industria
HIV, AIDS e malattie autoimmuni
Salute
Igiene alimentare
Biotecnologia
Medicina - Varie
Farmaceutica
ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
11/03/2025
Eventi
Industria
Scienza
Biotecnologia
Farmaceutica
HIV, AIDS e malattie autoimmuni
Sanità
Salute
ViiV Healthcare showcases leadership in long-acting injectables innovation at CROI 2025 with data on third-generation integrase inhibitor (INSTI) and highly potent capsid inhibitor against HIV-1
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0